Stomach Neoplasms
📧 Sign up to get email alerts when something new happens for Stomach Neoplasms.
Sign up freeTop drugs studied for this disease
-
EMA withdrawal · 2022-12-13EMA Application withdrawn: Tuznue (trastuzumab) — Prestige Biopharma Belgium
The EMA has withdrawn the application for Tuznue (trastuzumab) by Prestige Biopharma Belgium.
-
EMA withdrawal · 2022-12-13EMA Application withdrawn: Hervelous (trastuzumab) — Prestige Biopharma Belgium
The EMA indicates an application for Hervelous (trastuzumab) by Prestige Biopharma Belgium has been withdrawn.
-
EMA withdrawal · 2022-05-20EMA Withdrawn: Docetaxel Zentiva (previously Docetaxel Winthrop) (docetaxel) — Zentiva k.s.
The EMA has withdrawn Docetaxel Zentiva (docetaxel) from the market. The therapeutic areas formerly associated include head and neck neoplas…
-
CLINICAL_TRIALS withdrawal · 2021-12-16Clinical Trial Update: Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension [Phase 3]
A Phase 3 trial (MK-3475-859/KEYNOTE-859) evaluating pembrolizumab plus chemotherapy versus placebo plus chemotherapy in gastric/GEJ adenoca…
-
EMA withdrawal · 2021-12-14EMA Withdrawn: Docetaxel Teva (docetaxel) — Teva B.V.
The EMA has withdrawn Docetaxel Teva, an injectable chemotherapy containing docetaxel, from the European market.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA withdrawal · 2019-10-15EMA Withdrawn: Taxespira (previously Docetaxel Hospira UK Limited ) (docetaxel trihydrate) — Hospira UK Limited
The EMA withdrew Taxespira (docetaxel trihydrate) from the market for multiple cancer indications including stomach, prostate, breast, head …
-
CLINICAL_TRIALS withdrawal · 2018-03-12Clinical Trial Update: Density of Neurons in the Stomach and Prognosis of Gastric Adenocarcinoma [NA]
The clinical trial NCT01821196 evaluating neuronal density in the stomach and prognosis of gastric adenocarcinoma has been withdrawn.
-
EMA withdrawal · 2016-12-22EMA Withdrawn: Capecitabine SUN (capecitabine) — Sun Pharmaceutical Industries Europe B.V.
Capecitabine SUN (capecitabine) has been withdrawn from the European market by Sun Pharmaceutical Industries Europe B.V.
-
EMA withdrawal · 2012-06-14EMA Withdrawn: Docefrez (docetaxel) — Sun Pharmaceutical Industries Europe B.V.
Withdrawn EMA entry for Docefrez (docetaxel) by Sun Pharmaceutical Industries Europe B.V.; listed indications include stomach neoplasms, ade…
-
EMA withdrawal · 2010-03-26EMA Application withdrawn: Docetaxel Mylan (docetaxel) — Mylan S.A.S.
Withdrawal of the EMA application for Docetaxel Mylan (docetaxel) by Mylan S.A.S., affecting multiple solid tumor indications including non-…